Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01131000 · ClinicalTrials.gov registry record · Phase 3

Efficacy, Safety, and Pharmacokinetics of Intravenous Ibuprofen in Adult Febrile Patients

A Phase 3 study of Fever, sponsored by Cumberland Pharmaceuticals.

Completed
Registry status
Phase 3
Development phase
123
Enrollment target
11
Study locations

NCT01131000 is a Phase 3 study of Fever that has completed, run by Cumberland Pharmaceuticals. The registered enrollment target is 123 participants, below the 593-participant average among 18 other Fever trials with a reported enrollment target (79% lower). The trial reports 11 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01131000, a Phase 3 study of Fever, has completed, sponsored by Cumberland Pharmaceuticals.

COMPLETED
Registry status
Phase 3
Development phase
123 participants
Enrollment target
11
Study locations

Study Summary

The primary objective of this study is to evaluate the efficacy of intravenous ibuprofen on reducing fever at 4 hours.

Conditions Studied

Interventions

  • DRUG Ibuprofen
  • OTHER Normal Saline

Study Locations (11)

Tennessee

  • Methodist Healthcare - University Hospital - Memphis
  • Vanderbilt University Medical Center - Nashville
  • Skyline Medical Center - Nashville

North Carolina

  • Moses H. Cone Memorial Hospital - Greensboro
  • Wake Forest University Health Sciences - Winston-Salem

Florida

  • Orlando Regional Medical Center - Orlando

Missouri

  • Barnes Jewish Hospital - St Louis

Texas

  • Ben Taub General Hospital - Houston

New South Wales

  • Newcastle Mater Misericordiae Hospital - New Lambton

South Australia

  • Flinders Medical Centre - Adelaide

Other

  • Mahidol University Siriraj Hospital - Bangkok

Trial Details

FieldValue
Enrollment Target 123 participants
Start Date 2002-06
Est. Completion 2005-08
Phase Phase 3

Sponsor

Cumberland Pharmaceuticals

43 total trials

What the Registry Record Tells You About NCT01131000

The ClinicalTrials.gov registry entry for NCT01131000 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 593-participant average among 18 other Fever trials with a reported enrollment target (79% lower). The listed sponsor is Cumberland Pharmaceuticals, which has 43 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Fever appearing as the primary indexed condition, and to 2 interventions - of which Ibuprofen is the first listed.

NCT01131000 reports 11 study locations spanning 8 distinct geographic areas - top geographies include Tennessee, North Carolina, Florida.

Frequently Asked Questions

What is clinical trial NCT01131000 about?

NCT01131000 is a clinical study titled "Efficacy, Safety, and Pharmacokinetics of Intravenous Ibuprofen in Adult Febrile Patients". The primary objective of this study is to evaluate the efficacy of intravenous ibuprofen on reducing fever at 4 hours.

What is the current status of trial NCT01131000?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 123 participants. The study started on 2002-06. Estimated completion is 2005-08.

What conditions does trial NCT01131000 study?

This clinical trial studies the following conditions: Fever.

What interventions are being tested in trial NCT01131000?

The interventions under investigation include: Ibuprofen (DRUG), Normal Saline (OTHER).

Who is sponsoring clinical trial NCT01131000?

This trial is sponsored by Cumberland Pharmaceuticals, which has 43 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01131000 being conducted?

This trial has 11 study locations across Florida, Missouri, North Carolina, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Fever

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.